BACKGROUND: The mechanism of human immunodeficiency virus (HIV) transmission via heterosexual intercourse is unknown. We sought to determine whether the presence of inflammatory cells in the vagina is associated with the presence of genital tract HIV type 1 (HIV-1) RNA. METHODS: Analysis of a longitudinal prospective cohort was performed. Women with HIV-1 infection were assessed with use of paired plasma and cervicovaginal lavage specimens. Viral load measurements were performed using nucleic acid sequence-based amplification. White blood cells found in the genital tract (GT WBCs) were quantified using a hemacytometer. Common lower genital tract infections assessed for association with viral shedding (i.e., genital tract viral load [GTVL]) included bacterial vaginosis, candidiasis, and trichomoniasis. Generalized estimating equations were used to estimate the prevalence and odds of detectable GTVL by GT WBC. The association was examined both in the presence and in the absence of lower genital tract infections. RESULTS: A total of 97 women and 642 visits were included in the analysis. Median duration of follow-up was 30.4 months. Thirty women (31%) had detectable GTVL at any visit. The median CD4 cell count at baseline was 525 cells/muL. Most women were antiretroviral therapy naive at baseline. After adjustment for plasma viral load, the odds of detectable GTVL increased as GT WBC increased, with an odds ratio of 1.36 (95% confidence interval, 1.1-1.7) per 1000-cell increase in GT WBC among women without lower genital tract infections. After adjustment for plasma viral load and lower genital tract infections by incorporating them in a regression model, GT WBC remained significantly associated with GTVL, with an adjusted odds ratio of 1.22 (95% confidence interval, 1.08-1.37). CONCLUSIONS: The presence of GT WBC is associated with an increased risk of detectable GTVL.
BACKGROUND: The mechanism of human immunodeficiency virus (HIV) transmission via heterosexual intercourse is unknown. We sought to determine whether the presence of inflammatory cells in the vagina is associated with the presence of genital tract HIV type 1 (HIV-1) RNA. METHODS: Analysis of a longitudinal prospective cohort was performed. Women with HIV-1 infection were assessed with use of paired plasma and cervicovaginal lavage specimens. Viral load measurements were performed using nucleic acid sequence-based amplification. White blood cells found in the genital tract (GT WBCs) were quantified using a hemacytometer. Common lower genital tract infections assessed for association with viral shedding (i.e., genital tract viral load [GTVL]) included bacterial vaginosis, candidiasis, and trichomoniasis. Generalized estimating equations were used to estimate the prevalence and odds of detectable GTVL by GT WBC. The association was examined both in the presence and in the absence of lower genital tract infections. RESULTS: A total of 97 women and 642 visits were included in the analysis. Median duration of follow-up was 30.4 months. Thirty women (31%) had detectable GTVL at any visit. The median CD4 cell count at baseline was 525 cells/muL. Most women were antiretroviral therapy naive at baseline. After adjustment for plasma viral load, the odds of detectable GTVL increased as GT WBC increased, with an odds ratio of 1.36 (95% confidence interval, 1.1-1.7) per 1000-cell increase in GT WBC among women without lower genital tract infections. After adjustment for plasma viral load and lower genital tract infections by incorporating them in a regression model, GT WBC remained significantly associated with GTVL, with an adjusted odds ratio of 1.22 (95% confidence interval, 1.08-1.37). CONCLUSIONS: The presence of GT WBC is associated with an increased risk of detectable GTVL.
Authors: R H Gray; M J Wawer; R Brookmeyer; N K Sewankambo; D Serwadda; F Wabwire-Mangen; T Lutalo; X Li; T vanCott; T C Quinn Journal: Lancet Date: 2001-04-14 Impact factor: 79.321
Authors: A Kovacs; L S Chan; Z C Chen; W A Meyer; L Muderspach; M Young; K Anastos; A M Levine Journal: J Acquir Immune Defic Syndr Date: 1999-10-01 Impact factor: 3.731
Authors: C C Wang; R S McClelland; M Reilly; J Overbaugh; S R Emery; K Mandaliya; B Chohan; J Ndinya-Achola; J Bwayo; J K Kreiss Journal: J Infect Dis Date: 2001-02-28 Impact factor: 5.226
Authors: M Laga; A Manoka; M Kivuvu; B Malele; M Tuliza; N Nzila; J Goeman; F Behets; V Batter; M Alary Journal: AIDS Date: 1993-01 Impact factor: 4.177
Authors: C J Miller; D W Kang; M Marthas; Z Moldoveanu; H Kiyono; P Marx; J H Eldridge; J Mestecky; J R McGhee Journal: Clin Exp Immunol Date: 1992-06 Impact factor: 4.330
Authors: D J Anderson; T R O'Brien; J A Politch; A Martinez; G R Seage; N Padian; C R Horsburgh; K H Mayer Journal: JAMA Date: 1992-05-27 Impact factor: 56.272
Authors: Caroline Mitchell; Jane Hitti; Kathleen Paul; Kathy Agnew; Susan E Cohn; Amneris E Luque; Robert Coombs Journal: AIDS Res Hum Retroviruses Date: 2010-10-07 Impact factor: 2.205
Authors: Seth C Kalichman; Chauncey Cherry; Moira O Kalichman; Lisa A Eaton; James J Kohler; Catherine Montero; Raymond F Schinazi Journal: J Acquir Immune Defic Syndr Date: 2018-05-01 Impact factor: 3.731
Authors: Catherine A Blish; R Scott McClelland; Barbra A Richardson; Walter Jaoko; Kishorchandra Mandaliya; Jared M Baeten; Julie Overbaugh Journal: J Acquir Immune Defic Syndr Date: 2012-12-01 Impact factor: 3.731
Authors: Anna Gibbs; Taha Hirbod; Qingsheng Li; Karin Bohman; Terry B Ball; Francis A Plummer; Rupert Kaul; Joshua Kimani; Kristina Broliden; Annelie Tjernlund Journal: J Immunol Date: 2014-03-17 Impact factor: 5.422
Authors: Seth C Kalichman; Christopher Washington; Tamar Grebler; Moira O Kalichman; Chauncey Cherry; Lisa Eaton Journal: Int J STD AIDS Date: 2014-05-27 Impact factor: 1.359